PharmaCyte Biotech Inc (PMCB)

[efood125]

3 things to happen during 2020...

"There are 3 milestones specifically that shareholders should be mindful of that could generate the kind of price appreciation that biotech investors have come to enjoy in both big and small bio/pharma companies with each of these same expected milestone announcements."


"The first of those milestones, which shareholders should be prepared for, is the submission of an Investigational New Drug application (IND) to the U.S. FDA requesting authorization to administer its investigational therapy to humans in a proposed Phase 2b clinical trial."

Following the submission of an IND, even greater anticipation will grow for what could be a momentous milestone and one that would essentially be announced only weeks later.  The second of the 3 milestones that shareholders will be eyeing is the FDA’s response to PharmaCyte’s request to begin a clinical trial.  After submission, the FDA will notify PharmaCyte of the date it receives the application through an IND acknowledgment letter, and it is that date that starts the clock on the FDA’s 30-day response time.

With an IND in effect, the suspense among shareholders and the biotech community for the third and undoubtedly the most exciting of the upcoming 2020 milestones would be palpable—the enrollment of the first patient.